论文部分内容阅读
目的探讨阿奇霉素对支原体肺炎患儿心肌损伤的影响。方法选取医院2010年2月至2015年2月收治的支原体肺炎患儿80例,按随机数字表法分为治疗组和对照组,各40例。对照组患儿给予常规退烧药和止咳药对症治疗,治疗组患儿在对照组治疗基础上给予阿奇霉素治疗。观察两组患儿心肌酶谱、肌钙蛋白I(cTnI)、肌红蛋白(MB)、糖原磷酸化酶同工酶(GPBB)等指标的变化。结果治疗后,治疗组患儿的天门冬酸氨基转移酶(AST)、乳酸脱氢酶(LDH)、肌酸激酶(CK)、α-羟丁酸脱氢酶(α-HBDH)和肌酸激酶同工酶(CK-MB)水平分别为(20.42±11.45)U/L,(123.35±83.71)U/L),(120.42±53.45)U/L,(90.49±48.32)U/L和(10.29±4.92)U/L,对照组患儿的分别为(58.52±21.19)U/L,(493.45±93.82)U/L,(500.12±143.45)U/L,(319.49±118.42)U/L和(27.16±11.92)U/L,治疗组患儿的各项指标均明显低于对照组患儿(P<0.05);治疗组患儿的cTnI水平为(0.12±0.06)μg/L,明显低于对照组的(0.29±0.10)μg/L(P<0.05);治疗组患儿的MB水平为(40.10±19.24)μg/L,明显低于对照组患儿的(156.91±71.23)μg/L(P<0.05);治疗组患儿的GPBB水平为(3.75±1.02)μg/L,明显低于对照组患儿的(6.75±2.13)μg/L(P<0.05)。结论支原体肺炎患儿通常有心肌损害并发症,阿奇霉素在有效治疗支原体肺炎的同时,还能较好地减轻甚至治疗并发的心肌损伤。
Objective To investigate the effect of azithromycin on myocardial injury in children with mycoplasma pneumonia. Methods Eighty children with mycoplasmal pneumonia admitted from February 2010 to February 2015 in our hospital were divided into treatment group and control group according to random number table method, 40 cases in each group. Children in the control group were given conventional antipyretic drugs and antitussive symptomatic treatment. Children in the treatment group were treated with azithromycin on the basis of the control group. The changes of cardiac enzymes, cTnI, myoglobin (MB), and glycogen phosphorylase isoenzyme (GPBB) in the two groups were observed. Results After treatment, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatine kinase (CK), α-hydroxybutyrate dehydrogenase (α-HBDH) and creatine The levels of CK-MB were (20.42 ± 11.45) U / L, (123.35 ± 83.71) U / L, 120.42 ± 53.45 U / L and 90.49 ± 48.32 U / 10.29 ± 4.92) U / L and (58.52 ± 21.19) U / L respectively in the control group (493.45 ± 93.82) U / L, (500.12 ± 143.45) U / L and (319.49 ± 118.42) U / L And (27.16 ± 11.92) U / L, respectively. The indexes in the treatment group were significantly lower than those in the control group (P <0.05). The cTnI level in the treatment group was (0.12 ± 0.06) μg / L (0.29 ± 0.10) μg / L (P <0.05) in the control group. The MB level in the treatment group was (40.10 ± 19.24) μg / L, which was significantly lower than that in the control group (156.91 ± 71.23) μg /L(P<0.05). The GPBB level of the treatment group was (3.75 ± 1.02) μg / L, which was significantly lower than that of the control group (6.75 ± 2.13) μg / L (P <0.05). Conclusion Mycoplasma pneumonia children usually have complications of myocardial damage, azithromycin in the effective treatment of mycoplasma pneumonia, but also can better reduce or even treat concurrent myocardial injury.